Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Dosimetric benefit of a new ophthalmic radiation plaque.

Marwaha G, Wilkinson A, Bena J, Macklis R, Singh AD.

Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1226-30. doi: 10.1016/j.ijrobp.2012.01.084. Epub 2012 Jun 1.

PMID:
22658440
2.
3.

Lack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma.

Yousef YA, Finger PT.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1107-12. doi: 10.1016/j.ijrobp.2011.09.033. Epub 2011 Dec 13.

PMID:
22172910
4.

Dosimetric verification of a dedicated 3D treatment planning system for episcleral plaque therapy.

Knutsen S, Hafslund R, Monge OR, Valen H, Muren LP, Rekstad BL, Krohn J, Dahl O.

Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1159-66.

PMID:
11704341
5.

Novel low-kVp beamlet system for choroidal melanoma.

Esquivel C Jr, Fuller CD, Waggener RG, Wong A, Meltz M, Blough M, Eng TY, Thomas CR Jr.

Radiat Oncol. 2006 Sep 11;1:36.

6.

A five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve.

Finger PT, Chin KJ, Tena LB.

Ophthalmology. 2012 Feb;119(2):415-22. doi: 10.1016/j.ophtha.2011.08.017. Epub 2011 Nov 30.

PMID:
22133796
7.

125I plaque therapy for uveal melanoma. Analysis of the impact of time and dose factors on local control.

Quivey JM, Augsburger J, Snelling L, Brady LW.

Cancer. 1996 Jun 1;77(11):2356-62.

PMID:
8635107
8.

Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects.

Jones R, Gore E, Mieler W, Murray K, Gillin M, Albano K, Erickson B.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):989-95.

PMID:
11958893
9.

Improved treatment planning for COMS eye plaques.

Astrahan MA.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1227-42.

PMID:
15752905
10.

Iodine brachytherapy as an alternative to enucleation for large uveal melanomas.

Puusaari I, Heikkonen J, Summanen P, Tarkkanen A, Kivelä T.

Ophthalmology. 2003 Nov;110(11):2223-34.

PMID:
14597534
11.

Proliferative radiation retinopathy after plaque radiotherapy for uveal melanoma.

Bianciotto C, Shields CL, Pirondini C, Mashayekhi A, Furuta M, Shields JA.

Ophthalmology. 2010 May;117(5):1005-12. doi: 10.1016/j.ophtha.2009.10.015. Epub 2010 Jan 15.

PMID:
20079924
12.

A reanalysis of the Collaborative Ocular Melanoma Study Medium Tumor Trial eye plaque dosimetry.

Krintz AL, Hanson WF, Ibbott GS, Followill DS.

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):889-98.

PMID:
12788199
13.

Risk factors for neovascular glaucoma after proton beam therapy of uveal melanoma: a detailed analysis of tumor and dose-volume parameters.

Mishra KK, Daftari IK, Weinberg V, Cole T, Quivey JM, Castro JR, Phillips TL, Char DH.

Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):330-6. doi: 10.1016/j.ijrobp.2013.05.051. Epub 2013 Jul 23.

PMID:
23886415
14.

Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study.

Saconn PA, Gee CJ, Greven CM, McCoy TP, Ekstrand KE, Greven KM.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):844-8. doi: 10.1016/j.ijrobp.2009.08.059. Epub 2010 Feb 19.

PMID:
20171804
15.

Monte Carlo simulation of COMS ophthalmic applicators loaded with Bebig I25.S16 seeds and comparison with planning system predictions.

Miras H, Terrón JA, Lallena AM.

Phys Med. 2013 Nov;29(6):670-6. doi: 10.1016/j.ejmp.2012.07.003. Epub 2012 Jul 31.

PMID:
22858007
16.

Dosimetric and late radiation toxicity comparison between iodine-125 brachytherapy and stereotactic radiation therapy for juxtapapillary choroidal melanoma.

Krema H, Heydarian M, Beiki-Ardakani A, Weisbrod D, Xu W, Laperriere NJ, Sahgal A.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):510-5. doi: 10.1016/j.ijrobp.2013.02.005. Epub 2013 Mar 16.

PMID:
23507292
17.

Delivered dose uncertainty analysis at the tumor apex for ocular brachytherapy.

Morrison H, Menon G, Larocque MP, Jans HS, Weis E, Sloboda RS.

Med Phys. 2016 Aug;43(8):4891. doi: 10.1118/1.4959540.

PMID:
27487906
18.

Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.

Chiu-Tsao ST, Astrahan MA, Finger PT, Followill DS, Meigooni AS, Melhus CS, Mourtada F, Napolitano ME, Nath R, Rivard MJ, Rogers DW, Thomson RM.

Med Phys. 2012 Oct;39(10):6161-84. doi: 10.1118/1.4749933.

PMID:
23039655
19.

Comparison of 16 mm OSU-Nag and COMS eye plaques.

Zhang H, Davidorf F, Qi Y.

J Appl Clin Med Phys. 2012 May 10;13(3):3632. doi: 10.1120/jacmp.v13i3.3632.

20.

Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.

Browne AW, Dandapani SV, Jennelle R, Stevanovic M, Lee TC, Murphree AL, Kampp TD, Astrahan MA, Kim JW, Berry JL.

Brachytherapy. 2015 Sep-Oct;14(5):718-25. doi: 10.1016/j.brachy.2015.04.010. Epub 2015 Jun 12.

PMID:
26073224

Supplemental Content

Support Center